KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Acquisitions (2016)

Historic Acquisitions for Biomarin Pharmaceutical (BMRN) over the last 5 years, with Q4 2016 value amounting to $1.3 million.

  • Biomarin Pharmaceutical's Acquisitions changed N/A to $1.3 million in Q4 2016 from the same period last year, while for Dec 2017 it was $1.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.8 million for FY2016, which is 9948.2% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Acquisitions stood at $1.3 million for Q4 2016.
  • In the past 5 years, Biomarin Pharmaceutical's Acquisitions registered a high of $538.4 million during Q1 2015, and its lowest value of $1.3 million during Q4 2016.
  • Moreover, its 3-year median value for Acquisitions was $9.9 million (2013), whereas its average is $183.2 million.